Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F24%3AE0111070" target="_blank" >RIV/00843989:_____/24:E0111070 - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38" target="_blank" >https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2024013212" target="_blank" >10.1182/bloodadvances.2024013212</a>
Alternative languages
Result language
angličtina
Original language name
Targeting CD38 with isatuximab and a novel CD38/CD3xCD28 trispecific T-cell engager in older patients with acute myeloid leukemia
Original language description
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and its prevalence significantly increases in older patients. Furthermore, while the 5-year rate of overall survival (OS) for adults younger than 60 is around 40%, it decreases to 10% in patients above this age. The treatment landscape of AML is evolving from a curative/intensive vs palliative/low-intensity binary approach into new strategies that incorporate mutation-specific targeted therapies, apoptosis-inducing small molecules, and immunotherapy. Nonetheless, older patients who are unable to receive intensive chemotherapy with acceptable side effects and patients with relapsed/refractory disease continue to have dismal survival rates. Thus, the identification of new targets and treatment modalities is an unmet need.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood advances
ISSN
2473-9537
e-ISSN
2473-9537
Volume of the periodical
8
Issue of the periodical within the volume
15
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
3875-3879
UT code for WoS article
001284281200001
EID of the result in the Scopus database
2-s2.0-85201467266